Several other research firms have also weighed in on DHR. Robert W. Baird restated a buy rating and issued a $99.00 target price on shares of Danaher in a report on Friday, December 15th. Citigroup boosted their target price on Danaher to $107.00 and gave the stock a buy rating in a report on Friday, December 15th. Morgan Stanley boosted their target price on Danaher from $95.00 to $98.00 and gave the stock an overweight rating in a report on Friday, October 20th. Zacks Investment Research upgraded Danaher from a hold rating to a buy rating and set a $97.00 target price for the company in a report on Thursday, October 5th. Finally, J P Morgan Chase & Co restated an overweight rating and issued a $95.00 target price on shares of Danaher in a report on Friday, September 8th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $94.38.
Shares of Danaher (NYSE:DHR) opened at $94.38 on Tuesday. The stock has a market capitalization of $65,650.00, a PE ratio of 24.26, a PEG ratio of 2.23 and a beta of 1.02. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. Danaher has a 1-year low of $77.66 and a 1-year high of $94.84.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend is Thursday, December 28th. Danaher’s dividend payout ratio is currently 16.67%.
In other news, CAO Robert S. Lutz sold 11,189 shares of the business’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $91.66, for a total transaction of $1,025,583.74. Following the sale, the chief accounting officer now directly owns 18,314 shares in the company, valued at $1,678,661.24. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total value of $11,671,620.96. Following the completion of the sale, the chief executive officer now owns 271,737 shares in the company, valued at $25,173,715.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in the business. National Asset Management Inc. boosted its stake in Danaher by 0.4% in the second quarter. National Asset Management Inc. now owns 3,767 shares of the conglomerate’s stock worth $318,000 after purchasing an additional 14 shares in the last quarter. First Financial Corp IN boosted its stake in Danaher by 0.8% in the second quarter. First Financial Corp IN now owns 2,720 shares of the conglomerate’s stock worth $230,000 after purchasing an additional 21 shares in the last quarter. Brighton Jones LLC boosted its stake in Danaher by 0.4% in the second quarter. Brighton Jones LLC now owns 5,159 shares of the conglomerate’s stock worth $435,000 after purchasing an additional 21 shares in the last quarter. Buckingham Asset Management LLC lifted its stake in shares of Danaher by 0.4% during the second quarter. Buckingham Asset Management LLC now owns 5,778 shares of the conglomerate’s stock valued at $488,000 after acquiring an additional 24 shares during the period. Finally, Simmons Bank lifted its stake in shares of Danaher by 0.4% during the second quarter. Simmons Bank now owns 7,160 shares of the conglomerate’s stock valued at $604,000 after acquiring an additional 26 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2017/12/20/danaher-dhr-given-hold-rating-at-credit-suisse-group.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.